NCT07025538View on ClinicalTrials.gov

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 9, 2025

Primary Completion Date

October 9, 2025

Study Completion Date

October 9, 2025

Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
OTHER

Best Practice

Receive SOC treatment

OTHER

Biomarker Analysis

Undergo GHVD biomarker analysis

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Ruxolitinib

Given PO

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER